Incidence and predictors of hypocalcemia in end-stage renal disease patients on denosumab therapy: A systematic review and meta-analysis

doi:10.13105/wjma.v12.i3.97256

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1734)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

HTML

920

Figures (1-3)

123

Tables (1-2)

113

Sum=1190

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

157

Download

237

Sum=394

Publishing Process of This Article

Item

Count

Browse

Download

Sum=110

Sep 18, 2024 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Meta-Analysis

ISSN

2308-3840

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Meta-Anal. Sep 18, 2024; 12(3): 97256
Published online Sep 18, 2024. doi: 10.13105/wjma.v12.i3.97256

Open in New Tab Full Size Figure Download Figure

Figure 1 Preferred Reporting Items for Systematic Review and Meta-analyses flowchart. LTE: Letter to the Editor.

Open in New Tab Full Size Figure Download Figure

Figure 2 Forest plots for primary outcomes. A: Mild hypocalcemia; B: Severe hypocalcemia; C: Very severe hypocalcemia. CI: Confidence interval.

Open in New Tab Full Size Figure Download Figure

Figure 3 Forest plots for secondary outcomes. A: Change in serum calcium; B: Change in serum intact parathyroid hormone; C: Change in serum phosphate. CI: Confidence interval.

Citation: Siddiqui AH, Shaikh M, Salman A, Fahim MAA, Batool F, Mari T, Musani S, Fareed M, Rehan R, Hassni A, Nizami U, Amir A, Moeed A, Surani SR. Incidence and predictors of hypocalcemia in end-stage renal disease patients on denosumab therapy: A systematic review and meta-analysis. World J Meta-Anal 2024; 12(3): 97256
URL: https://www.wjgnet.com/2308-3840/full/v12/i3/97256.htm
DOI: https://dx.doi.org/10.13105/wjma.v12.i3.97256